# CJC-1295: Duration Is Part of the Molecule > CJC-1295 Research Overview — Research Peptide Fundamentals — Research Peptide Fundamentals research peptides: CJC-1295 structure, DAC versus no-DAC, GHRH receptor signaling, human pharmacology, cautions, and assay context. **04 / ENGINEERED ANALOGUE** An engineered GHRH analogue shows how albumin binding changes exposure—and why DAC and no-DAC forms cannot be interpreted as the same compound. ## The short version CJC-1295 is a synthetic version of part of growth-hormone-releasing hormone, or GHRH. It activates a receptor in the pituitary gland, which then stimulates the growth-hormone and IGF-1 axis. Early human studies measured those hormone changes directly [20][21][22]. The name hides an important distinction. CJC-1295 with DAC includes a chemical group that binds circulating albumin and keeps the molecule active for days. The material often called CJC-1295 no-DAC or Modified GRF 1-29 lacks that albumin-binding feature and is much shorter acting. Mixing the names makes study results and safety discussions unreliable. Human pharmacology confirms prolonged endocrine activity for the DAC form, but this is not proof of long-term health, performance, or anti-aging benefit. CJC-1295 is not an approved medicine, its development program did not produce an approved indication, and it is prohibited in tested sport. The evidence supports a mechanism and exposure profile, not personal-use protocols. ## What it is CJC-1295 is built on the first twenty-nine residues of human growth-hormone-releasing factor. Four amino-acid substitutions stabilize its helical structure and reduce several breakdown routes. In the DAC variant, a maleimide-containing linker reacts with a free thiol on serum albumin, forming a covalent peptide-albumin conjugate. Albumin binding slows clearance and extends exposure. The no-DAC form retains the stabilizing substitutions but lacks the albumin-binding moiety. Its duration is fundamentally different. “CJC-1295” is therefore not a sufficient methods description; investigators need exact molecular form, formulation, and analytical identity. Laboratory mass spectrometry has identified CJC-1295 in an unknown seized preparation, illustrating the quality-control and anti-doping context surrounding unregulated material [19]. ## How it works CJC-1295 binds the GHRH receptor on anterior-pituitary somatotroph cells. Receptor activation engages Gs, cyclic AMP, and protein kinase A signaling, leading to synthesis and release of growth hormone. Growth hormone then stimulates hepatic production of insulin-like growth factor 1, creating a measurable endocrine cascade [18]. The DAC form does not merely produce a stronger version of a short pulse. Its engineered persistence changes the time course of receptor stimulation. Human work found that the natural pulsatile pattern of growth-hormone secretion continued even while baseline stimulation was elevated [22]. An assay may measure peak concentration, mean concentration, trough level, pulse frequency, or a downstream protein signature, and those endpoints answer different questions. ## What the research shows *Hormone exposure.* In healthy adults, studied administrations of the long-acting form produced multi-fold increases in mean plasma growth hormone lasting several days, smaller but prolonged increases in IGF-1, and an estimated half-life measured in days [21]. Those findings describe early pharmacology under controlled conditions; they are not dosing advice. *Pulsatility.* A related study in healthy men found higher basal and mean growth hormone and higher IGF-1 one week after administration while pulse frequency and magnitude remained intact [22]. This supports the claim that continuous stimulation can raise the baseline without erasing pulsatile secretion. *Proteomic assay.* In eleven healthy young men, serum proteomics identified shifts in several protein species, and some changes correlated with IGF-1 [20]. The study proposes candidate biomarkers of axis activation; it does not demonstrate clinical benefit. *Class and analytical context.* A current endocrine review explains the receptor pharmacology and rationale for long-acting GHRH analogue design [18]. High-resolution analytical chemistry also identified CJC-1295 in a seized preparation [19], underscoring that label claims in uncontrolled markets are not chemical verification. ## Reported effects, cautions & safety **The following is anecdotal, not clinical evidence.** Research-use communities very commonly describe deeper sleep and water retention. Faster workout recovery, a leaner appearance, tingling in the hands, and injection-site reactions are frequently reported. Other accounts mention energy changes, flushing, fatigue, headache, appetite change, or higher blood sugar. These reports are uncontrolled, vulnerable to co-use and expectation effects, and cannot establish frequency or causation. Cautions follow from evidence and mechanism. Sustained GH/IGF-1 stimulation can affect fluid balance and insulin sensitivity, and prolonged pathway activation raises unresolved theoretical questions. The DAC and no-DAC forms create different exposure patterns, so conflating them distorts risk interpretation. The compound is not approved for human use, and no large or long-term trial establishes safety or effectiveness in healthy adults. The corpus also records regulator concern about immunogenicity, discontinued development with unresolved reporting around a death, and prohibition in sport. Early human studies establish endocrine action; they do not settle broader safety questions [18][21][22]. ## Where it fits in Research Peptide Fundamentals CJC-1295 is the engineered counterpoint to the biologically derived peptides in this digest. Its origin story is rational design: stabilize a GHRH fragment, optionally attach an albumin-binding system, and measure the endocrine time course. Here, molecular form determines exposure, and exposure determines what an assay sees. Compared with [GHK-Cu](/ghk-cu), the pathway is more receptor-specific. Compared with [KPV](/kpv) and [MOTS-c](/mots-c), CJC-1295 has direct human intervention data, though the data remain early and pharmacological rather than outcome-driven. Its lesson is precise: evidence that a molecule engages its intended axis is necessary, but it is not sufficient evidence of long-term benefit, safety, or suitability for use. ![CJC-1295 research illustration](/images/cjc-1295.webp) --- Genesis Peptides Lab independently traces peptide claims from biological origin to measurable assay; it is a literature digest, not a clinic, vendor, or source of medical advice.